SCHEMBL26375472

SCHEMBL26375472

CC(C)CCCOCCOCCOCCNC(=O)CCC(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.44
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40
GLP1R P43220 8/20 0.39
CNR1 P21554 2/20 0.39
CNR2 P34972 1/20 0.39
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA4 P22748 2/20 0.37
CA9 Q16790 2/20 0.37
CA14 Q9ULX7 2/20 0.37
GPBAR1 Q8TDU6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24433548 0.93 TSHR (0.47) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL13616087 0.93 MEN1 (0.53) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL19871922 0.90 CNR1 (0.46) MEN1KMT2AALDH1A1HPGDTSHR
SCHEMBL24433547 0.90 TSHR (0.47) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL11912094 0.90 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL21029891 0.90 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL11912095 0.90 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL11912086 0.88 ALDH1A1 (0.50) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL25480646 0.88 TSHR (0.54) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL23334540 0.87 TSHR (0.51) MEN1KMT2AALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS RAB1A, SOS1, IQGAP1 MEN1 236/4885KMT2A 4124/4885ALDH1A1 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.